<DOC>
	<DOCNO>NCT00593151</DOCNO>
	<brief_summary>The purpose PLUS study confirm safety tolerability two dos LocteronTM ( 320 ug 640 ug ) dose four week patient fail prior anti-HCV therapy ( Panels A B ) , continue study safety , tolerability , preliminary efficacy two dos LocteronTM ( 320 ug 640 ug ) treatment-naïve genotype 1 HCV patient Locteron dose 12 week ( Panel C ) . All subject also receive oral daily weight-based ribavirin .</brief_summary>
	<brief_title>Study Safety , Tolerability , Anti-Viral Effect Locteron Compared PEG-Intron Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>Panels A B PLUS study design assess safety tolerability , pharmacokinetics , viral kinetics four week two dos Locteron™ ( 230 ug 640 ug ) give every two week comparison PegIntron® give weekly treatment-experienced subject chronic hepatitis C genotype co-administered weight-based oral ribavirin . The two cohort 16 subject Panels A B consisted subject fail prior interferon therapy . In Panel A , 8 subject randomize complete 4 week treatment 320 μg Locteron™ 8 subject randomize complete 4 week treatment 1.5 ug/kg PegIntron® . In Panel B , 8 subject randomize complete 4 week treatment 640 μg Locteron™ 8 subject randomize complete 4 week treatment 1.5 ug/kg PegIntron® . When result Panel A Panel B know , conduct Panel C 12 week treatment-naive patient chronic genotype-1 HCV consider unnecessary cancelled , entirely new study begin instead .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Evidence chronic hepatitis C Positive HCV RNA test level &gt; = 1 x 104 IU/mL ( RTPCR ) Decompensated Liver Disease Positive test serum antibody human immunodeficiency virus ( HIV ) , hepatitis A ( HAVIgM ) , hepatitis B ( HBV +Hepatitis B surface antigen ) A history severe psychiatric disease , include major depression A history immunologicallymediated disease , COPD , severe asthma , severe cardiac disease , active cancer cancer within last 5 year , seizure within past 5 year epilepsy , solid organ bone marrow transplant , uncontrolled thyroid disease , clinically significant retinopathy Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Antimetabolites</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Molecular Mechanisms Action</keyword>
	<keyword>Pharmacologic Actions</keyword>
</DOC>